

## PRESS RELEASE



### Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Calif., and SUZHOU, China and SHANGHAI, China, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in two upcoming investor conferences.

#### **Citi 2023 Virtual Oncology Leadership Summit**

Fireside Chat: February 21<sup>st</sup> at 10:00 am ET

#### **H.C. Wainwright Cell Therapy Virtual Conference**

Fireside Chat: February 28<sup>th</sup> at 9:30 am ET

One-on-one meetings: Tuesday, February 28<sup>th</sup>, 2023

A webcast of the presentations will be available on the [News and Events](#) section of the Company's website. A replay of the webcast will be available for 90 days following the event. For more information, please visit [ir.gracellbio.com](http://ir.gracellbio.com).

#### **About Gracell**

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CART™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit <http://www.gracellbio.com/>. Follow [@GracellBio](#) on LinkedIn.

Media contact Marvin Tang [marvin.tang@gracellbio.com](mailto:marvin.tang@gracellbio.com) Investor contact Gracie Tong [gracie.tong@gracellbio.com](mailto:gracie.tong@gracellbio.com)